Empagliflozin Targeting STAT3/Akt/Nrf2 Axis Promoting Diabetic Wound Healing in Rat Model

    September 2025 in “ Frontiers in Pharmacology ”
    Rania Magadmi, Dalal Alfawaz, Ahmed Bakhshwin, Fatmah Alghamdi, Sultan A. Alfawaz, Duaa Bakhshwin, Maha Jamal, Roba A. Sofi, Ahmed Esmat
    TLDR Empagliflozin helps heal diabetic wounds in rats by reducing inflammation and oxidative stress.
    The study examined the effects of empagliflozin on diabetic wound healing in 50 male Wistar rats, focusing on the STAT3/Akt/Nrf2 axis. Empagliflozin, administered orally or as a hydrogel, significantly improved wound healing, with oral administration showing the greatest efficacy, achieving 80.24% wound contraction by day 21. The treatment reduced inflammatory markers (TNF-α, IL-6) and oxidative stress, increased antioxidant activity (GSH, SOD), and activated key signaling pathways (STAT3, Akt, Nrf2). These findings suggest empagliflozin's potential as a therapeutic agent for diabetic wound management due to its anti-inflammatory and antioxidant properties.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results